Dr Tricia Tan is a Consultant in Diabetes, Endocrinology and Metabolic Medicine at Imperial College London and NHS Trust. She possesses over 10 years’ experience in gut hormone research and physiological studies into the impact of gut hormones on weight and T2DM. She has completed several Phase I trials on the gut hormone analogues, which are being developed for the treatment of obesity. She is the director of the SAS Gut Hormone service, and her clinical research spans a wide gamut from the diagnosis and treatment of neuroendocrine tumours to diagnostic testing in Endocrine disorders.
et al., 2022, Changes in circulating kisspeptin levels during each trimester in women with antenatal complications, Journal of Clinical Endocrinology and Metabolism, Vol:107, ISSN:0021-972X, Pages:e71-e83
et al., 2021, Preserved C-peptide in survivors of COVID-19: post-hoc analysis, Diabetes, Obesity and Metabolism: a Journal of Pharmacology and Therapeutics, ISSN:1462-8902
et al., 2021, A glucagon analogue decreases body weight in mice via signalling in the liver., Scientific Reports, Vol:11, ISSN:2045-2322, Pages:1-17
Khoo B, Tan TM-M, 2021, Surpassing insulin glargine in type 2 diabetes with tirzepatide., Lancet, Vol:398, Pages:1779-1781
et al., 2021, Can current methods of predicting T2D remission following metabolic surgery be improved?, 12th Annual Scientific Meeting of the British-Obesity-and-Metabolic-Surgery-Society (BOMSS), SPRINGER, Pages:S13-S13, ISSN:0960-8923